Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL184536

CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OC(CC)C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC.O=S(=O)(O)C(F)(F)F

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
NR5A2 O00482 2/20 0.57
NR5A1 Q13285 2/20 0.57
ALDH1A1 P00352 1/20 0.53
FABP3 P05413 1/20 0.51
MAPT P10636 1/20 0.51
SELP P16109 1/20 0.51
SLC6A5 Q9Y345 1/20 0.50
PRKCE Q02156 1/20 0.48
PRKCQ Q04759 1/20 0.48
PRKCD Q05655 1/20 0.48
PRKCA P17252 1/20 0.48
DAGLA Q9Y4D2 2/20 0.48
ENPP2 Q13822 2/20 0.48
LPAR3 Q9UBY5 4/20 0.47
LPAR1 Q92633 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021533 0.93 SMN1; SMN2 (0.66) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL327161 0.93 SMN1; SMN2 (0.66) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL3502856 0.93 SMN1; SMN2 (0.66) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL160176 0.91 SMN1; SMN2 (0.63) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL747961 0.87 SMN1; SMN2 (0.74) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL672430 0.87 SMN1; SMN2 (0.74) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL326877 0.87 SMN1; SMN2 (0.74) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL326926 0.87 SMN1; SMN2 (0.74) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL5698359 0.87 SMN1; SMN2 (0.74) SMN1; SMN2NR5A2NR5A1ALDH1A1FABP3
SCHEMBL18628315 0.84 S1PR1 (0.61) SMN1; SMN2NR5A2NR5A1ALDH1A1SELP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150196589-A1 FORMULATIONS FOR ALTERATION OF BIOPHYSICAL PROPERTIES OF MUCOSAL LINING PULMATRIX, INC. 2015-07-16 US disclosed
EP-2402001-A1 Formulations for alteration of biophysical properties of mucosal lining Pulmatrix, Inc. (US) 2012-01-04 EP disclosed
EP-2308469-A1 Formulations for alteration of biophysical properties of mucosal lining Pulmatrix, Inc. (US) 2011-04-13 EP disclosed
WO-2010103514-A1 SILICA NANOCAPSULES FROM NANO-EMULSIONS OBTAINED BY PHASE INVERSION YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2010-09-16 WO disclosed
EP-1906922-A2 FORMULATIONS FOR ALTERATION OF BIOPHYSICAL PROPERTIES OF MUCOSAL LINING Pulmatrix, Inc. (US) 2008-04-09 EP disclosed
US-20080038207-A1 Method and device for decreasing contamination PULMATRIX, INC. 2008-02-14 US disclosed
US-20070053844-A1 FORMULATIONS FOR ALTERATION OF BIOPHYSICAL PROPERTIES OF MUCOSAL LINING PULMATRIX INC. 2007-03-08 US disclosed
WO-2006125153-A2 FORMULATIONS FOR ALTERATION OF BIOPHYSICAL PROPERTIES OF MUCOSAL LINING PULMATRIX INC. (US) 2006-11-23 WO disclosed